Trial shows risvutatug rezetecan significantly improves overall survival in relapsed small-cell lung cancer

Results from the randomized Phase III ARTEMIS-008 proceedings amusement that risvutatug rezetecan (Ris-Rez), a B7-H3-directed antibody-drug conjugate, importantly improved wide endurance compared with topotecan successful patients with relapsed small-cell lung crab (SCLC) whose illness progressed connected oregon aft platinum-based chemotherapy. The findings were presented contiguous astatine the IASLC 2026 World Conference connected Lung Cancer (WCLC).